EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Uptake Patterns of [18F]Fluoroestradiol PET/MRI in Benign Breast Lesions and Molecular Breast Cancer Subtypes

Thomas Spiegel iD, Sazan Rasul iD, Nina Pötsch, Alexander Stiglbauer-Tscholakoff, Panagiotis Kapetas iD, Lukas Nics, Paulina Gebhart, Ivo Rausch iD, Zsuzsanna Bago-Horvath, Paola Clauser, Pascal A T Baltzer iD, Marcus Hacker iD und 2 weitere

Cancers · 20.02.2026 · 18 (4) · 696

DOI: 10.3390/cancers18040696 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 20.02.2026. Verfasst von Thomas Spiegel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Imaging and Image-Guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Waehringer Guer…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Vienna Science and Technology Fund (WWTF), Jubiläumsfonds der Österreichischen Nationalbank.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Estrogen receptor (ER) expression is a key biomarker in breast cancer (BC) and guides endocrine therapy selection. Estrogen receptor-targeted imaging with 16ɑ-[18F]-fluoro-17β-estradiol (18F-FES) PET is recommended in several clinical guidelines for noninvasive assessment of ER status. In clinical practice, 18F-FES PET may also identify ER-negative malignancies or benign breast lesions with variable uptake patterns. This study aimed to systematically characterize 18F-FES PET/MRI uptake patterns in benign breast lesions and across breast cancer subtypes defined by receptor status, histology, and molecular phenotype.

Methods

This retrospective single-center study included 41 women with 50 breast lesions who underwent simultaneous 18F-FES PET/MRI prior to any treatment. Histopathology or long-term follow-up served as the standard of reference. Maximum and mean standardized uptake values (SUVmax and SUVmean) were derived using MRI-based lesion delineation.

Results

Both benign and malignant breast lesions measuring < 10 mm demonstrated low 18F-FES uptake (SUVmax < 1.00). 18F-FES uptake among benign breast lesions was variable, with SUVmax ranging from 0.44 to 1.57. In contrast, ER-positive lesions ≥ 10 mm exhibited substantially higher 18F-FES uptake (median SUVmax 2.76; range 1.23–9.74) compared with ER-negative tumors of similar size (SUVmax 0.30–0.94). 18F-FES uptake was consistent across histologic BC subtypes and did not differ significantly among ER-positive molecular subtypes. No significant associations were observed with HER2 status or tumor grade.

Conclusions

Awareness of the heterogeneous 18F-FES uptake patterns in benign breast lesions, as well as the limited sensitivity for detecting ER-positive tumors < 10 mm, is essential for accurate image interpretation. 18F-FES PET/MRI enables reliable assessment of ER expression in BC lesions ≥ 10 mm, with uptake patterns remaining consistent across molecular and histologic subtypes.

Schlagwörter

Stichwörter der Autor:innen

18F-FluoroestradiolPET/MRIbenign breast lesionsbreast cancermolecular imagingmolecular subtypes

Autor:innen und Institutionen

  • Department of Biomedical Imaging and Image-Guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
  • Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
  • Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
  • Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
  • Department of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
  • Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY 10065, USA.

ORCID-Profile: Thomas Spiegel, Sazan Rasul, Panagiotis Kapetas, Ivo Rausch, Pascal A T Baltzer, Marcus Hacker, Thomas H Helbich

Förderung

  • NCI NIH HHS
  • Vienna Science and Technology Fund (WWTF)
  • Jubiläumsfonds der Österreichischen Nationalbank

Zitieren

APA

Spiegel, T., Rasul, S., Pötsch, N., Stiglbauer-Tscholakoff, A., Kapetas, P., Nics, L., Gebhart, P., Rausch, I., Bago-Horvath, Z., Clauser, P., Baltzer, P. A. T., Hacker, M., Helbich, T. H., & Pinker, K. (2026). Uptake Patterns of [18F]Fluoroestradiol PET/MRI in Benign Breast Lesions and Molecular Breast Cancer Subtypes. Cancers, 18(4), 696. https://doi.org/10.3390/cancers18040696

Vancouver

Spiegel T, Rasul S, Pötsch N, Stiglbauer-Tscholakoff A, Kapetas P, Nics L, et al. Uptake Patterns of [18F]Fluoroestradiol PET/MRI in Benign Breast Lesions and Molecular Breast Cancer Subtypes. Cancers. 2026;18(4):696. doi:10.3390/cancers18040696

BibTeX
@article{Spiegel2026,
  author = {Spiegel, Thomas and Rasul, Sazan and Pötsch, Nina and Stiglbauer-Tscholakoff, Alexander and Kapetas, Panagiotis and Nics, Lukas and Gebhart, Paulina and Rausch, Ivo and Bago-Horvath, Zsuzsanna and Clauser, Paola and Baltzer, Pascal A T and Hacker, Marcus and Helbich, Thomas H and Pinker, Katja},
  title = {Uptake Patterns of [18F]Fluoroestradiol PET/MRI in Benign Breast Lesions and Molecular Breast Cancer Subtypes},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {4},
  pages = {696},
  doi = {10.3390/cancers18040696}
}
Kostenlos starten →